Recombinant Human SNU13 Protein, N-His from ProteoGenix; catalogue ARO-P11994; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant proteins are proteins that are produced through genetic engineering techniques, where a specific gene is inserted into a host organism, such as bacteria or yeast, to produce a large amount of the desired protein. Recombinant proteins have become an essential tool in various fields of research, including medicine, biotechnology, and biochemistry.
One such recombinant protein is the Recombinant Human SNU13 Protein, which has gained significant attention in recent years due to its unique structure, diverse functions, and potential applications. In this article, we will delve into the details of this protein, including its structure, activity, and potential applications.
The Recombinant Human SNU13 Protein, also known as small nuclear ribonucleoprotein-associated protein N, is a 13 kDa protein that is encoded by the SNU13 gene located on chromosome 12 in humans. This protein is highly conserved among eukaryotes, with a 100% sequence identity between human and yeast SNU13 proteins.
The protein is composed of 116 amino acids and has a unique structure consisting of two domains, an N-terminal domain, and a C-terminal domain. The N-terminal domain is responsible for binding to RNA, while the C-terminal domain interacts with other proteins, such as small nuclear ribonucleoproteins (snRNPs), to form the core of the spliceosome complex.
The structure of Recombinant Human SNU13 Protein has been extensively studied using X-ray crystallography, which has revealed its compact and globular shape. The protein is also known to undergo post-translational modifications, such as phosphorylation and acetylation, which can affect its activity and function.
The primary function of Recombinant Human SNU13 Protein is in pre-mRNA splicing, a crucial process in gene expression that involves removing introns and joining exons to form mature mRNA. This protein plays a vital role in this process by stabilizing the interaction between snRNPs and pre-mRNA, thereby facilitating the formation of the spliceosome complex.
Additionally, Recombinant Human SNU13 Protein has been shown to interact with other proteins involved in RNA processing, such as RNA helicases, suggesting its involvement in other RNA-related activities. It has also been reported to have a role in regulating mRNA stability and translation, further highlighting its diverse functions.
The activity of Recombinant Human SNU13 Protein is also influenced by its binding to specific RNA sequences, such as the stem-loop structure found in the U4 snRNA. This binding has been shown to enhance the stability of the spliceosome complex, thus promoting efficient pre-mRNA splicing.
Given its crucial role in pre-mRNA splicing and other RNA-related activities, Recombinant Human SNU13 Protein has potential applications in various fields of research and medicine.
One of the primary applications of this protein is in the study of pre-mRNA splicing and the spliceosome complex. Recombinant Human SNU13 Protein can be used to investigate the mechanism of splicing and its regulation, as well as to identify potential therapeutic targets for diseases associated with splicing defects, such as cancer.
Moreover, Recombinant Human SNU13 Protein has been used in the development of diagnostic tools for detecting RNA-related diseases. For example, its interaction with specific RNA sequences can be utilized to design probes for detecting RNA biomarkers in diseases such as Alzheimer’s and Parkinson’s.
Furthermore, Recombinant Human SNU13 Protein has potential applications in biotechnology, such as in the production of recombinant proteins. Its high affinity for RNA can be exploited to develop RNA-protein fusion tags for protein purification
ProteoGenix catalogue number ARO-P11994. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 16.34 kDa; Fragment: Met1-Val128; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
